LT3347360T - Junginiai, naudingi ror-gama-t slopinimui - Google Patents

Junginiai, naudingi ror-gama-t slopinimui

Info

Publication number
LT3347360T
LT3347360T LTEP16766765.8T LT16766765T LT3347360T LT 3347360 T LT3347360 T LT 3347360T LT 16766765 T LT16766765 T LT 16766765T LT 3347360 T LT3347360 T LT 3347360T
Authority
LT
Lithuania
Prior art keywords
gamma
compounds useful
inhibiting ror
ror
inhibiting
Prior art date
Application number
LTEP16766765.8T
Other languages
English (en)
Inventor
John Richard Morphy
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT3347360T publication Critical patent/LT3347360T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP16766765.8T 2015-09-09 2016-09-06 Junginiai, naudingi ror-gama-t slopinimui LT3347360T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09
PCT/US2016/050374 WO2017044410A1 (en) 2015-09-09 2016-09-06 Compounds useful for inhibiting ror-gamma-t

Publications (1)

Publication Number Publication Date
LT3347360T true LT3347360T (lt) 2020-01-27

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16766765.8T LT3347360T (lt) 2015-09-09 2016-09-06 Junginiai, naudingi ror-gama-t slopinimui

Country Status (41)

Country Link
US (1) US9598431B1 (lt)
EP (1) EP3347360B1 (lt)
JP (1) JP6282789B1 (lt)
KR (1) KR102048780B1 (lt)
CN (1) CN108026112B (lt)
AR (1) AR105821A1 (lt)
AU (1) AU2016318593B2 (lt)
BR (1) BR112018001451B1 (lt)
CA (1) CA2994732C (lt)
CL (1) CL2018000558A1 (lt)
CO (1) CO2018002440A2 (lt)
CR (1) CR20180089A (lt)
CY (1) CY1122287T1 (lt)
DK (1) DK3347360T3 (lt)
DO (1) DOP2018000066A (lt)
EA (1) EA033882B1 (lt)
EC (1) ECSP18018793A (lt)
ES (1) ES2760992T3 (lt)
HK (1) HK1249901B (lt)
HR (1) HRP20192235T1 (lt)
HU (1) HUE047950T2 (lt)
IL (1) IL257202B (lt)
JO (1) JO3638B1 (lt)
LT (1) LT3347360T (lt)
MA (1) MA42776B1 (lt)
MD (1) MD3347360T2 (lt)
MX (1) MX2018002898A (lt)
MY (1) MY195903A (lt)
NZ (1) NZ739518A (lt)
PE (1) PE20181274A1 (lt)
PH (1) PH12018500504A1 (lt)
PL (1) PL3347360T3 (lt)
PT (1) PT3347360T (lt)
RS (1) RS59655B1 (lt)
SI (1) SI3347360T1 (lt)
SV (1) SV2018005647A (lt)
TN (1) TN2018000057A1 (lt)
TW (1) TWI597284B (lt)
UA (1) UA118824C2 (lt)
WO (1) WO2017044410A1 (lt)
ZA (1) ZA201800515B (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2871911T3 (es) * 2017-03-02 2021-11-02 Lilly Co Eli Compuestos útiles para inhibir ROR-gamma-t
PT3589637T (pt) * 2017-03-02 2021-06-02 Lilly Co Eli Compostos úteis para inibir ror-gamma-t
WO2018193297A1 (en) 2017-04-21 2018-10-25 Cadila Healthcare Limited Novel compounds as ror-gamma modulators
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
WO2022122740A1 (en) 2020-12-07 2022-06-16 Diaccurate Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
JP5723381B2 (ja) * 2009-11-16 2015-05-27 イーライ リリー アンド カンパニー Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物
NZ767139A (en) * 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
MX367341B (es) * 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX2014014614A (es) * 2012-05-31 2015-02-12 Phenex Pharmaceuticals Ag Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano ror [gamma).
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
WO2015017335A1 (en) 2013-07-30 2015-02-05 Boehringer Ingelheim International Gmbh Azaindole compounds as modulators of rorc
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators

Also Published As

Publication number Publication date
MX2018002898A (es) 2018-06-18
AR105821A1 (es) 2017-11-15
KR102048780B1 (ko) 2019-11-27
HK1249901B (zh) 2020-06-19
MA42776B1 (fr) 2020-02-28
IL257202A (en) 2018-03-29
SI3347360T1 (sl) 2019-12-31
US20170066781A1 (en) 2017-03-09
CN108026112B (zh) 2020-04-10
DOP2018000066A (es) 2018-03-30
ZA201800515B (en) 2019-06-26
US9598431B1 (en) 2017-03-21
ES2760992T3 (es) 2020-05-18
NZ739518A (en) 2019-06-28
CY1122287T1 (el) 2020-11-25
MD3347360T2 (ro) 2020-03-31
JO3638B1 (ar) 2020-08-27
EA033882B1 (ru) 2019-12-05
DK3347360T3 (da) 2020-01-02
CR20180089A (es) 2018-02-27
PH12018500504A1 (en) 2018-09-24
CA2994732A1 (en) 2017-03-16
EP3347360A1 (en) 2018-07-18
HRP20192235T1 (hr) 2020-03-20
MY195903A (en) 2023-02-27
CL2018000558A1 (es) 2018-08-10
HUE047950T2 (hu) 2020-05-28
PT3347360T (pt) 2020-01-07
CN108026112A (zh) 2018-05-11
JP2018507203A (ja) 2018-03-15
CA2994732C (en) 2020-06-30
EA201890364A1 (ru) 2018-08-31
ECSP18018793A (es) 2018-04-30
BR112018001451A2 (pt) 2018-09-11
EP3347360B1 (en) 2019-10-23
TN2018000057A1 (en) 2019-07-08
PL3347360T3 (pl) 2020-04-30
TWI597284B (zh) 2017-09-01
RS59655B1 (sr) 2020-01-31
WO2017044410A1 (en) 2017-03-16
CO2018002440A2 (es) 2018-07-10
UA118824C2 (uk) 2019-03-11
JP6282789B1 (ja) 2018-02-21
TW201722964A (zh) 2017-07-01
SV2018005647A (es) 2018-07-23
AU2016318593A1 (en) 2018-02-15
PE20181274A1 (es) 2018-08-03
IL257202B (en) 2020-02-27
AU2016318593B2 (en) 2018-10-04
BR112018001451B1 (pt) 2023-10-10
KR20180031777A (ko) 2018-03-28

Similar Documents

Publication Publication Date Title
GB201510019D0 (en) Compounds
GB201514754D0 (en) Compounds
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
GB201514751D0 (en) Compounds
GB201508747D0 (en) Compounds
RS61999B1 (sr) Jedinjenja
GB201508864D0 (en) Compounds
IL253813A0 (en) Compounds of the diaza-benzofluoroanthrene type and preparations containing these compounds
RS61935B1 (sr) Jedinjenja korisna za inhibiciju ror-gama-t
GB201510493D0 (en) Compounds
SI3589638T1 (sl) Spojine uporabne pri inhibiciji ROR-GAMMA-T
GB201508857D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
GB201519965D0 (en) Compounds
GB201519212D0 (en) Compounds
GB201519213D0 (en) Compounds
GB201516445D0 (en) Compounds
GB201516059D0 (en) Compounds
GB201512279D0 (en) Compounds
GB201511387D0 (en) Compounds
GB201511064D0 (en) Compounds
GB201510910D0 (en) Compounds
GB201510760D0 (en) Compounds
GB201508866D0 (en) Compounds